Delving into the Latest Updates on Pneumococcal polysaccharide conjugate vaccine with Synapse

Overview

Basic Info

Drug Type

Prophylactic vaccine, Multivalent vaccine, Conjugated vaccine

Synonyms

13-Valent Pneumococcal Polysaccharide Conjugate Vaccine, 13vPnC, Pneumococcal 13-valent Conjugate Vaccine (Diphtheria CRM197 Protein)

+ [10]

Target-

Mechanism

Immunostimulants

Therapeutic Areas

Infectious DiseasesOtorhinolaryngologic DiseasesRespiratory Diseases+ [2]

Active Indication

Pneumonia, BacterialAcute otitis mediaInvasive streptococcal disease+ [5]

Inactive Indication

Haemophilus InfectionsHematopoietic stem cell transplantationHIV Infections+ [1]

Originator Organization

Pfizer Inc.

Active Organization

Pfizer Europe MA EEIG

Pfizer Investment Co. Ltd.Wyeth Pharmaceuticals LLC

+ [4]

Inactive Organization

Haleon (Suzhou) Pharmaceutical Co. Ltd.

GSK PlcWyeth Lederle Vaccines SA

+ [1]

Drug Highest PhaseApproved

First Approval Date

JP (16 Oct 2009),

Pneumococcal Infections

Regulation-

Login to view timeline

A Parallel-group Prevention, Phase II, Partially Blinded, Multi-stage Study to Investigate the Immunogenicity and Safety of Pentavalent Meningococcal ABCYW Vaccine Formulations Compared With Licensed Meningococcal Vaccines When Administered Alone in Healthy Children (2 to 9 Years of Age) or Concomitantly With Routine Pediatric Vaccines in Toddlers (12 to 15 Months of Age) and Infants (2 Months of Age).

This study is the first study of Sanofi's Pentavalent Meningococcal ABCYW vaccine clinical development program to be conducted in the pediatric population below 10 years of age. The aim of the study is to assess 2 formulations of the MenPenta vaccine compared to licensed meningococcal vaccines when administered alone in children (Stage 1) or concomitantly with routine pediatric vaccines in toddlers (Stage 2) and infants (Stage 3).
Study details include:
The study duration per participant will be up to 12 months for children in Stage 1 and toddlers in Stage 2 and 16 to-19 months for infants in Stage 3.

Start Date05 Nov 2024

Sponsor / Collaborator

Sanofi Pasteur

TCTR20230923001

/ Not yet recruitingPhase 4

Immunogenicity and Safety of Pneumococcal 13-valent Conjugate Vaccine between Weuphoria and Prevnar 13 in Thai Older People

Start Date01 Nov 2024

Sponsor / Collaborator-

NCT06202703

/ RecruitingNot ApplicableIIT

Optimisation of Lymph Node Fine Needle Aspiration to Study Pneumococcal Vaccine-induced Immunity

Rationale Causing a wide range of infectious diseases, including pneumonia, otitis media and meningitis, S. pneumoniae represents an important global health problem. Pneumococcal vaccines are clinically effective in preventing invasive pneumococcal disease, but the underlying immune response is likely to differ due to the inclusion of T cell epitopes in the conjugate, but not purified polysaccharide vaccine. However, these differences remain scantly studied. Lymph node fine needle aspiration (FNA) has been recently described to study vaccine-induced germinal centre responses in depth and represents a promising tool to study the underlying immune mechanisms of pneumococcal vaccines. Insight into the underlying immune mechanisms of vaccines could improve future vaccine design, e.g. by refining dosing intervals.
Objective Determine timing of peak germinal centre B cell frequency following pneumococcal vaccination.
Main trial endpoints The main trial endpoint is represented by the frequency of germinal centre B cells (BGC) in lymph node aspirates at various time points after vaccination, as measured by spectral flow cytometry. Both total BGC cells and S. pneumoniae polysaccharide-specific BGC frequencies will be determined.
Trial design Pilot intervention study without a comparator.
Trial population Healthy individuals between the age of 20 - 40
Interventions Subjects will be vaccinated once with Prevenar13. FNA of the draining lymph node will be performed and blood will be drawn at baseline, followed by weekly collection during the first four weeks, every other week between weeks 4 - 8 and a final collection time point after 12 weeks, resulting in a total of 8 sampling time points over the course of three months. Draining lymph node size will be assessed by ultrasound every other day during the first two weeks and then alongside lymph node FNA for the remainder of the study.

Start Date15 Apr 2023

Sponsor / Collaborator

Academisch Ziekenhuis Leiden

100 Clinical Results associated with Pneumococcal polysaccharide conjugate vaccine

Login to view more data

100 Translational Medicine associated with Pneumococcal polysaccharide conjugate vaccine

Login to view more data

100 Patents (Medical) associated with Pneumococcal polysaccharide conjugate vaccine

Login to view more data

1,067

Literatures (Medical) associated with Pneumococcal polysaccharide conjugate vaccine

01 Mar 2025·CARBOHYDRATE POLYMERS

Simplified process for preparing native and depolymerized capsular polysaccharides of Streptococcus pneumoniae

Article

Author: Huang, Xueting ; Liu, Jiankai ; Li, Yuelong ; Gao, Zhixin ; Yao, Hantian ; Liu, Yanli ; Zheng, Haifa ; Cao, Xin ; Zhang, Jing-Ren ; Wang, Jianlong

Streptococcus pneumoniae is a major pathogen of bacterial pneumonia, meningitis, sepsis, and otitis media. The pathogenicity of this bacterium is largely attributed to its polysaccharide capsule, a protective layer around bacterial cell that enables bacteria to resist against host defense. Capsular polysaccharides (CPSs) of S. pneumoniae have been used as antigens to develop a variety of pneumococcal vaccines against invasive pneumococcal disease (IPD). These vaccines have been proven to be effective in reducing the incidence of IPD cases that are caused by vaccine-covered serotypes at the global scale. A crucial step in the manufacture of pneumococcal polysaccharide and conjugate vaccines is to purify native and depolymerized CPSs to meet strict quality standards in purity and structural integrity. The major impurities comprise proteins, nucleic acids and cell wall polysaccharides (CWPS). Traditionally, the removal of impurities to obtain purified native CPSs involves a complex process of purification, after which purified CPSs need to be further size-reduced to obtain depolymerized CPSs by multi-step approaches. In this study, we streamlined the process of CPS purification, which involves firstly ultrafiltration, followed by one-step acid precipitation, and finally diafiltration to obtain pure native CPSs. Furthermore, hydrolysis using trifluoroacetic acid (TFA) was integrated into the process to obtain purified depolymerized CPSs. The native and depolymerized CPSs produced by this optimized process were comparable to the materials obtained by the traditional approaches in purity and structural integrity, which would meet the quality standards of CPSs for vaccine production in the current edition of the European Pharmacopeia.

01 Dec 2024·Infectious Diseases and Therapy

Global Epidemiology of Meningococcal Disease-Causing Serogroups Before and After the COVID-19 Pandemic: A Narrative Review

Review

Author: Shen, Steven ; Peyrani, Paula ; Findlow, Jamie

Invasive meningococcal disease (IMD) is associated with high morbidity and mortality and predominantly caused by five Neisseria meningitidis serogroups (A/B/C/W/Y). Polysaccharide conjugate vaccines induce T-cell-dependent immune responses, are immunogenic in infants and adults, and reduce carriage, and vaccination of age groups associated with high-carriage can provide indirect protection in the unvaccinated (herd immunity). Successful vaccination programs must be tailored to local epidemiology, which varies geographically, temporally, and by age and serogroup. Serogroup A IMD once predominated globally, but has largely disappeared following mass vaccination programs. Serogroup B was a predominant cause of IMD in many global regions from 2010 to 2018, typically affecting younger age groups. Spread of serogroup C clonal complex-11 IMD in the 1990s prompted implementation of MenC vaccine programs in many countries, resulting in declines in prevalence. Serogroup C still caused > 20% of global IMD through the mid-2010s. Serogroup W became a significant contributor to global IMD after Hajj pilgrimage outbreaks in 2000; subsequent increases of endemic disease and outbreaks were reported pre-pandemic in many regions. Serogroup Y emerged in the 1990s as a significant cause of IMD throughout various regions and prevalence had increased or stabilized from 2010 to 2018. Serogroup X is uncommon outside the African meningitis belt, and its prevalence has declined since before the COVID-19 pandemic. Global IMD declines during the pandemic were followed by resurgences generally caused by serogroups that were prevalent pre-pandemic and affecting mainly unvaccinated age groups (particularly adolescents/young adults). Recent IMD epidemiology underscores the importance of vaccinating at-risk age groups against regionally prevalent serogroups; for example, the anti-serogroup X component of the recently prequalified MenACWXY vaccine is likely to provide limited protection outside the African meningitis belt. In other regions, comprehensive vaccination against MenB and MenACWY, which could be streamlined by the recently approved MenABCWY vaccine, seems more appropriate.

01 Nov 2024·JOURNAL OF INFECTION

Comparison of short- and long-term humoral immune responses to pneumococcal polysaccharide and glycoconjugate vaccines in an HIV-infected population

Article

Author: Whitelegg, Alison ; MacLennan, Calman A. ; Birtwistle, Jane ; Plant, Timothy ; Shields, Adrian ; Manavi, Kaveh ; Hodson, James ; Richter, Alex ; Masuka, Sindiso ; MacLennan, Calman A ; Faustini, Siân E ; Drayson, Mark T ; Singo, Mebie ; Chigiga, Joyful ; Faustini, Siân E. ; Richter, Alex G ; Drayson, Mark T.

BACKGROUND:

Immunisation is recommended internationally to protect against pneumococcal infections in HIV-infected adults. However, vaccination schedule designs are mostly based on studies of initial rather than long-term antibody responses. This UK observational study investigated the short- and long-term antibody responses to polysaccharide and glycoconjugate pneumococcal vaccines in an adult HIV-infected cohort.

METHODS:

We studied a subgroup of 152 of 839 participants from the AIR (Assessment of Immune Responses to Routine Immunisations in HIV-infected Adults, ISRCTN95588307) study that had received pneumococcal vaccinations and had blood samples collected pre- and post-vaccination, as well as at least annually for four subsequent calendar years. Patients received either Pneumovax-23 (PPV, N = 89) or Prevenar-13 (PCV, N = 63) as their primary vaccine, with immunity assessed by measuring IgG antibody concentrations for 12 pneumococcal polysaccharide serotypes (PnPS). The primary outcome was achieving IgG antibody concentrations above the recommended World Health Organisation (WHO) threshold of 0.35 µg/mL for at least 8/12 of the PnPS assessed (WHO_≥8/12PnPS). Patients who did not achieve WHO_≥8/12PnPS after the primary vaccination were offered further vaccination with PCV; booster vaccinations with PCV were additionally offered to those where antibody levels subsequently fell below the WHO_≥8/12PnPS threshold.

RESULTS:

Patients receiving PCV as their primary pneumococcal vaccine were significantly more likely to achieve WHO_≥8/12PnPS after a single vaccine dose than those receiving PPV (54% vs. 33%, p = 0.012). This difference persisted following booster vaccination with PCV, with cumulative rates of WHO_≥8/12PnPS in those receiving PCV vs. PPV as the primary vaccine of 88% vs. 67% and 100% vs. 85% after receiving up to one and two booster vaccinations, respectively. Where WHO_≥8/12PnPS was achieved, this persisted significantly longer in those receiving PCV as their primary vaccine compared to PPV (median: 23.5 vs. 11.1 months; p = 0.010).

CONCLUSIONS:

Immunisation with PCV resulted in quantitatively greater antibody responses than immunisation with PPV in a cohort of HIV-infected UK adults. Individuals receiving PCV as their primary vaccine required fewer total pneumococcal vaccine doses to achieve WHO_≥8/12PnPS and experienced greater duration of time above this threshold than those with PPV as the primary vaccine. However, the median longevity of both vaccine responses was relatively short, which supports the use of ongoing booster doses using high-valency glycoconjugate vaccines to sustain WHO_≥8/12PnPS threshold antibody levels.

53

News (Medical) associated with Pneumococcal polysaccharide conjugate vaccine

30 Dec 2024

·www.globenewswire.com

Sanofi initiates phase 3 program for PCV21 and expands collaboration with SK bioscience for next-generation pneumococcal conjugate vaccines

Sanofi initiates phase 3 program for PCV21 and expands collaboration with SK bioscience for next-generation pneumococcal conjugate vaccines Pneumococcal disease remains a major global health challenge despite the availability of current vaccines This 21-valent pneumococcal conjugate vaccine (PCV21) is the first pneumococcal conjugate vaccine candidate with more than 20 serotypes to enter phase 3 in infants & toddlers December 23, 2024. Sanofi and SK bioscience have entered into a new chapter of their collaboration in pneumococcal vaccines with an expanded agreement to develop, license and commercialize next-generation PCVs for both pediatric and adult populations, reaffirming their commitment to fighting pneumococcal disease. Despite decades of public health vaccination programs, invasive pneumococcal disease (IPD) continues to inflict a substantial burden of disease, primarily due to Streptococcus pneumoniae serotypes that are not included in currently available conjugate vaccines. Next-generation PCVs have the potential to extend vaccine coverage of disease-causing serotypes. This expansion builds on the companies’ existing collaboration to develop and commercialize a PCV21 pediatric vaccine, for which the phase 3 clinical program commenced last week. This vaccine candidate is the first-ever PCV containing more than 20 serotypes to enter a phase 3 clinical study in infants and toddlers. Thomas Triomphe Executive Vice President, Vaccines, Sanofi “Given the vast unmet public health needs in IPD, we’re delighted to expand this collaboration and continue our pursuit of innovative work in PCV. Our collaboration leverages SK bioscience’s capabilities and Sanofi’s expertise in developing and bringing innovative vaccines to people worldwide with the collective aim of reducing the global impact of pneumococcal disease.” Jaeyong Ahn CEO and President of SK bioscience “We’re thrilled about the expansion of our collaboration with Sanofi, which serves as the core of our strategy to develop new solutions to combat pneumococcal disease. The ongoing expansion of our state-of-the-art manufacturing base, cofinanced by Sanofi, will support launch of PCV21 and future next generation vaccines.” The PCV21 phase 3 program is based on positive phase 2 results communicated last year and will include more than 7,700 infants, toddlers, young children and adolescents across multiple geographies, including the US, Europe, Australia, Asia, and Latin America. Under the terms of their expanded agreement, both companies will co-fund research and development costs. Sanofi will pay EUR 50M upfront to SK bioscience, followed by development and commercial milestone payments. Once registered, Sanofi will commercialize the vaccines worldwide except for South Korea, where SK bioscience will have commercial exclusivity. SK bioscience will receive royalty payments on product sales outside South Korea. We are an innovative global healthcare company, driven by one purpose: we chase the miracles of science to improve people’s lives. Our team, across the world, is dedicated to transforming the practice of medicine by working to turn the impossible into the possible. We provide potentially life-changing treatment options and life-saving vaccine protection to millions of people globally, while putting sustainability and social responsibility at the center of our ambitions. The content above comes from the network. if any infringement, please contact us to modify.

VaccineLicense out/in

03 Dec 2024

·www.echemi.com

Over 2,000 Layoffs in 19 Global Pharma Companies, Johnson & Johnson and Merck Restructure Operations in China

According to the latest monitoring data, at least 19 pharmaceutical companies globally announced layoffs or business streamlining plans in November. The impact on multinational pharmaceutical companies operating in China has been particularly significant, with Johnson & Johnson and Merck implementing layoffs in the country. Johnson & Johnson's layoffs in China reached 2,000 people, approximately 20% of its total workforce, mainly affecting the surgical division. The layoffs were primarily due to declining company performance, especially in its ultrasound knife business, which saw its market share plunge from 95% to less than 30%. Since the second quarter of this year, Johnson & Johnson has also undergone business adjustments, with several senior executives, including the president of China, Song Weiqun, leaving the company. Merck also conducted staff reductions in its China division, although the exact number of layoffs has not been specified, primarily affecting the diabetes department. Due to the impact of centralized procurement policies, Merck's diabetes drug business has suffered significantly, forcing the company to take measures to drastically reduce costs. In recent years, centralized procurement policies have driven down drug prices, leading to significant profit reductions for pharmaceutical companies, which have had to scale back or sell their operations in China in response. For example, Pfizer sold its PCV13 vaccine business and conducted extensive layoffs. In this context, other pharmaceutical companies have also announced restructuring plans. Sana Biotechnology is shifting its research focus from cancer to autoimmune diseases and has undergone strategic restructuring, though it has not disclosed the number of layoffs. Viracta Therapeutics, focusing on precision oncology, announced approximately 42% layoffs to concentrate resources on its Nana-val development project. Aurinia laid off 45% of its workforce due to an inability to find a buyer, aiming to maintain cash flow. A gene sequencing company announced a 40% reduction in staff and the termination of all therapeutic projects due to declining business and cash flow issues. Marinus Pharmaceuticals announced a 45% reduction in staff following the failure of its core drug in Phase III clinical trials. Adaptimmune stated it would lay off 33% of its workforce in Q1 2025, aiming to save $300 million over the next four years and achieve break-even by 2027. Additionally, companies such as Gilead, Sensei Biotherapeutics, Sonata, Lexicon Pharmaceuticals, Bristol-Myers Squibb, Alector, Medigene, Novartis, and Kronos Bio have also announced layoffs or restructuring plans to respond to the current challenges in the pharmaceutical industry. These measures reflect the strategies adopted by the pharmaceutical industry in the face of market changes and policy adjustments.

VaccinePhase 3Financial Statement

24 Oct 2024

·www.biospace.com

CDC Panel Recommends Merck and Pfizer Pneumococcal Vaccines for Adults Aged 50-64

The CDC’s Advisory Committee on Immunization Practices on Wednesday backed the use of Merck’s Capvaxive and Pfizer’s Prevnar 20 in adults between 50-64 years of age, opening a bigger market for the respective companies. An expert panel of the U.S. Centers for Disease Control and Prevention on Wednesday supported the broader use of pneumococcal vaccines, including adults between 19 and 49 years with certain risk factors, according to Reuters . The CDC’s Advisory Committee on Immunization Practices (ACIP) voted 14–1 in favor of expanding the agency’s guidance for pneumococcal vaccines—such as Merck ’s Capvaxive and Pfizer ’s Prevnar 20—to cover adults aged 50 to 64 years. These recommendations are not yet final and will still need final approval from the CDC director and the Department of Health and Human Services. Still, the new guidelines could unlock a bigger patient pool for Merck and Pfizer. Currently, the CDC only recommends pneumococcal vaccination for older adults 65 years and above , as well as in young adults aged 19 through 65 with certain risk conditions. A Merck spokesperson in an emailed statement welcomed the results of the ACIP vote, calling it a “potentially practice-changing decision” that could contribute to better immunization rates and health outcomes. The ACIP’s recommendations, if approved by the CDC director, “can help advance how we protect our communities from invasive pneumococcal disease and pneumococcal pneumonia,” the spokesperson said. Merck’s Capvaxive, which the FDA approved in June 2024 , is a 21-valent vaccine that targets the most prevalent serotypes, which cause around 84% of invasive pneumococcal disease in adults 50 years and older. A few weeks after approval, the CDC’s ACIP unanimously endorsed the use of Capvaxive. According to a Merck press release following the ACIP vote, the panel specifically recommends Capvaxive for adults aged 50 years and above who have not yet been immunized with a pneumococcal conjugate vaccine. The shot can also be given to vaccine-naïve younger adults 19 to 49 years with “certain underlying medical conditions” and other risk factors. The ACIP vote on Wednesday also presents a potential boon to Pfizer, which markets the 20-valent Prevnar 20. The FDA first approved the vaccine in June 2021 for adults 18 and above, and then in April 2023 to allow for pediatric use. Prevnar 20 improves upon Pfizer’s previous pneumococcal vaccine—Prevnar 13, which only covered 13 virus serotypes—and targets additional serotypes known to cause invasive pneumococcal disease or are associated with high fatality rates and antibiotic resistance. As in the case of Capvaxive, the ACIP on Wednesday backed the use of Prevnar 20 in older adults 50 years and older, and in 19-to-49-year-olds with certain risk factors, according to a Pfizer press release .

Drug ApprovalVaccine

100 Deals associated with Pneumococcal polysaccharide conjugate vaccine

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
-	Pneumococcal polysaccharide conjugate vaccine	J07AL02	-

R&D Status

Approved

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Pneumonia, Bacterial	JP	Pfizer Inc.	18 Jun 2013
Otitis Media	US	Wyeth Pharmaceuticals LLC	24 Feb 2010
Acute otitis media	EU	Pfizer Europe MA EEIG	09 Dec 2009
Acute otitis media	IS	Pfizer Europe MA EEIG	09 Dec 2009
Acute otitis media	LI	Pfizer Europe MA EEIG	09 Dec 2009
Acute otitis media	NO	Pfizer Europe MA EEIG	09 Dec 2009
Invasive streptococcal disease	EU	Pfizer Europe MA EEIG	09 Dec 2009
Invasive streptococcal disease	IS	Pfizer Europe MA EEIG	09 Dec 2009
Invasive streptococcal disease	LI	Pfizer Europe MA EEIG	09 Dec 2009
Invasive streptococcal disease	NO	Pfizer Europe MA EEIG	09 Dec 2009
Pneumonia, Pneumococcal	EU	Pfizer Europe MA EEIG	09 Dec 2009
Pneumonia, Pneumococcal	IS	Pfizer Europe MA EEIG	09 Dec 2009
Pneumonia, Pneumococcal	LI	Pfizer Europe MA EEIG	09 Dec 2009
Pneumonia, Pneumococcal	NO	Pfizer Europe MA EEIG	09 Dec 2009
Pneumococcal Infections	JP	Wyeth KK	16 Oct 2009

Developing

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Bacteremia	Phase 3	CN	John Wyeth & Brother Ltd.	23 Jun 2018
Bacteremia	Phase 3	CN	Pfizer Ltd.	23 Jun 2018
Bacteremia	Phase 3	CN	Wyeth Pharmaceuticals LLC	23 Jun 2018
Bacteremia	Phase 3	CN	Pfizer Investment Co. Ltd.	23 Jun 2018
Meningitis	Phase 3	CN	Wyeth Pharmaceuticals LLC	23 Jun 2018
Meningitis	Phase 3	CN	Pfizer Ltd.	23 Jun 2018
Meningitis	Phase 3	CN	John Wyeth & Brother Ltd.	23 Jun 2018
Meningitis	Phase 3	CN	Pfizer Investment Co. Ltd.	23 Jun 2018
invasive Streptococcus pneumoniae infection	Phase 3	CN	John Wyeth & Brother Ltd.	04 Sep 2012
invasive Streptococcus pneumoniae infection	Phase 3	CN	Wyeth Lederle Vaccines SA	04 Sep 2012

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT03691610 (CTgov)	Phase 3	Meningococcal Infections	950	MenACYW conjugate vaccine (Infants: Group 1)	nzwxlflyre(drijlrxyhr) = npddpqtspq aubtrvzpye (gbytlugagu, jlizrcgrha - aejdsahwpk) View more	-	25 Jun 2024
				MENVEO (Infants: Group 2)	nzwxlflyre(drijlrxyhr) = hezdhwdfel aubtrvzpye (gbytlugagu, wgqhnkqpae - pkdlbgrzmr) View more
NCT04535037 (CTgov)	Phase 4	Diphtheria	500	DTPa-HBV-IPV/Hib+Pneumococcal 13-valent conjugate vaccine (Infanrix Hexa)	jletjmlhxr(jltrndyeke) = tyerkrcjha urulsdagij (pxeafmuufo, ipuhjzhrdw - mrwbssnisv) View more	-	27 Mar 2024
				Pneumococcal 13-valent conjugate vaccine+DTaP5-HBV-IPV-Hib (Vaxelis)	jletjmlhxr(jltrndyeke) = sxlthuqkbn urulsdagij (pxeafmuufo, rratrxlkbt - gsjhwjtcgy) View more
NCT03630705 (MET33, CTgov)	Phase 3	Meningococcal Infections	525	Rubella Virus Vaccine Live+W) Tetanus Toxoid Conjugate Vaccine+Pneumococcal 13-valent Conjugate Vaccine+Rotavirus Vaccine, Live, Pentavalent (Group 1: MenACYW Conjugate Vaccine (Mexico))	hqimplgvje(wqfuqocmrc) = bqqgooknqz hfsztamkeu (spuhfptpne, ibyrxhyhwh - rwtdibjyzo) View more	-	19 Oct 2023
				Rubella Virus Vaccine Live+W) Tetanus Toxoid Conjugate Vaccine+Hepatitis B Vaccine+Haemophilus influenza type b Conjugate Vaccine+Diphtheria, Tetanus, Pertussis (Acellular, Component) Poliomyelitis (inactivated) Vaccine,+Pneumococcal 13-valent Conjugate Vaccine (Group 3: MenACYW Conjugate Vaccine (Russian Federation))	ryhboqscsx(wknhaqtnjt) = zpmzsbcvkk mfjjwjsepu (aatbrigvrr, zijzwysscl - askpskhqpl) View more
NCT03673462 (MET41, CTgov)	Phase 3	Meningococcal Infections	2,797	W) tetanus toxoid Conjugate vaccine (MenACYW Conjugate vaccine)+Diphtheria, Tetanus, Acellular Pertussis, Poliovirus+Varicella Virus Vaccine+Hepatitis B Vaccine+Pneumococcal 13-valent Conjugate Vaccine (Group 1: MenACYW Conjugate Vaccine)	cihabumwqh(spvgtfydgd) = cjkubmjoqw uyxruecqeq (luqdlghwxx, uhyfymofrd - sboiibglli) View more	-	05 Oct 2023
				W 135) Oligosaccharide Diphtheria CRM197 Conjugate Vaccine (MENVEO®)+Diphtheria, Tetanus, Acellular Pertussis, Poliovirus+Varicella Virus Vaccine+Hepatitis B Vaccine+Pneumococcal 13-valent Conjugate Vaccine (Group 2: MENVEO®)	cihabumwqh(spvgtfydgd) = dewtiholzb uyxruecqeq (luqdlghwxx, kycqcfqool - xlhdudstuv) View more
NCT05372575 (CTgov)	Not Applicable	Pneumonia	300	13-valent pneumococcal conjugate vaccine (13vPnC)+13vPnC (13vPnC Cohort)	nvwtmhwkms(zgwjanaxyj) = frrwcyvviy znijcboaii (yaedwcjelm, jfrcfohglb - utjiczkdqi) View more	-	03 Oct 2023
				13vPnC (Non-13vPnC Cohort)	nvwtmhwkms(zgwjanaxyj) = lrqbekcwao znijcboaii (yaedwcjelm, qntobckycs - afsvlyesex) View more
NCT02274415 (DREVAC, Pubmed)	Phase 2	Anemia, Sickle Cell	128	13-valent pneumococcal vaccinePPSV23eumococcal vaccine (PCV13/PPSV23)	nhzgnrdgpf(jpwocogcgv) = irxewkbtbw elmvajzjcn (rriqyofvdp ) View more	Positive	27 Jan 2023
				PPSV2313-valent pneumococcal vaccine (PPSV23 alone)	nhzgnrdgpf(jpwocogcgv) = uyvnzrcoou elmvajzjcn (rriqyofvdp ) View more
NCT03439657 (Pubmed \| J Infect)	Phase 3	-	913	Adjuvanted Recombinant Zoster Vaccine	xkoahvkcxw(dfadthjwvr): P-Value = 1.02 View more	Positive	25 Dec 2021
				13-valent Pneumococcal Conjugate Vaccine
NCT03550313 (CTgov)	Phase 2	Pneumococcal Infections	565	c7vPnC+Prevnar 13 (Group 1: c7vPnC and Prevnar 13 Co-administration)	okapfzhczj(ddskyrownt) = qmmlnmmrpc axlphomgni (kropwjuhvh, pfpscasbbj - aneorlezhh) View more	-	30 Nov 2021
				c7vPnC (Group 2: c7vPnC and Prevnar 13 Staggered Administration)	okapfzhczj(ddskyrownt) = dyvuohwsbc axlphomgni (kropwjuhvh, udcorrhrcn - bzkglwnbnh) View more
NCT03439657 (CTgov)	Phase 3	Herpes Zoster	913	HZ/su vaccine GSK1437173A+Prevenar13 (Co-Ad Group)	yihwegnghp(hqufplhvbv) = xdkabclyrh dicethpwvm (lxkkliwxis, jbemxtkake - qbpbuaizip) View more	-	18 Mar 2021
				HZ/su vaccine GSK1437173A+Prevenar13 (Control Group)	clfvmyfiai(wbneurtool) = joslfjpjzx zrzqqotgin (ceddzlpjwy, cpdpkderai - wfyuyigdxj) View more
NCT02309515 (CTgov)	Phase 2	Mannose-Binding Protein Deficiency \| Lymphocytosis \| Chronic Lymphocytic Leukemia ... View more	12	Laboratory Biomarker Analysis+Lenalidomide+Pneumococcal 13-valent Conjugate Vaccine (Arm I (Lenalidomide, Pneumococcal 13-valent Conjugate Vaccine))	erocncbmgc(nmvvucukgo) = gzwrlmqehn olriafbnlx (kpuhdxwxww, fabgnbtzdf - wzqogyeyga) View more	-	19 Jan 2021
				Laboratory Biomarker Analysis+Pneumococcal 13-valent Conjugate Vaccine (Arm II (Pneumococcal 13-valent Conjugate Vaccine))	erocncbmgc(nmvvucukgo) = tilccxwnye olriafbnlx (kpuhdxwxww, tjkgnnktru - hzvvifghst) View more